Tango Therapeutics (TNGX) – Investment Analysts’ Weekly Ratings Changes

by · The Markets Daily

Several analysts have recently updated their ratings and price targets for Tango Therapeutics (NASDAQ: TNGX):

  • 10/29/2026 – Tango Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $68.00 price target on the stock.
  • 10/27/2026 – Tango Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
  • 10/23/2026 – Tango Therapeutics was given a new $55.00 price target by Stifel Nicolaus.
  • 10/16/2026 – Tango Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX traded down $0.96 during trading on Monday, reaching $21.76. 3,681,588 shares of the stock were exchanged, compared to its average volume of 4,623,457. Tango Therapeutics, Inc. has a 12-month low of $7.37 and a 12-month high of $34.39. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -25.60 and a beta of 1.17. The firm’s 50-day moving average price is $23.56 and its 200 day moving average price is $22.28.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). As a group, equities research analysts forecast that Tango Therapeutics, Inc. will post -1.41 EPS for the current year.

Insiders Place Their Bets

In related news, insider Jessica Newcomb sold 8,200 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the completion of the sale, the insider directly owned 59,121 shares of the company’s stock, valued at approximately $1,431,910.62. This represents a 12.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Adam Crystal sold 27,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total transaction of $660,690.00. Following the sale, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $2,832,231.21. This trade represents a 18.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 6.50% of the company’s stock.

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.

Featured Articles